Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma

A combination of elotuzumab, an immunostimulatory monoclonal antibody, with lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma.

A combination of elotuzumab, an immunostimulatory monoclonal antibody, with lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. Researchers conducted a study involving patients whose multiple myeloma was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor. The patients were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone or a combination of pomalidomide plus dexamethasone. A total of 117 patients were randomly assigned to either the elotuzumab group or the control group. After a minimum followup period of 9.1 months, the median progression-free survival was 10.3 months in the elotuzumab group and 4.7 months in the control group. The most common grade 3 or 4 adverse events were neutropenia (13% in the elotuzumab group vs. 27% in the control group), anemia (10% vs. 20%), and hyperglycemia (8% vs. 7%). Approximately two-thirds of the patients in each group had infections, while 5% (3) of those in the elotuzumab group had infusion reactions. The researchers conclude, "The findings from this randomized trial showed that the addition of the monoclonal antibody elotuzumab to pomalidomide and dexamethasone resulted in a significant improvement over pomalidomide and dexamethasone alone in treatment outcomes of relapsed or refractory multiple myeloma."